The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington, - ppt download
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
Figure S1: CHAMPION PHOENIX Study Design | Download Scientific Diagram
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute€Coronar
Table 3 from Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. | Semantic Scholar
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Cangrelor Superior to Clopidogrel in CHAMPION PHOENIX Trial | DAIC
Figure1 | THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | JACC: Journal of the American College of Cardiology
Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention | JACC: Cardiovascular Interventions
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington, - ppt download
Table 1 from Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention | Semantic Scholar
CHAMPION PHOENIX trial
Subanalyses of the CHAMPION PHOENIX trial. | Download Scientific Diagram
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
BCRI - Clinical Trials
Pro Position: The Data - Phoenix and Meta-Analysis of the Champion Clinical Trial Program! | tctmd.com
THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | Journal of the American College of Cardiology
Efficacy outcomes at 30 days in CHAMPION-PHOENIX trial. | Download Table
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM